Tocilizumab (Actemra, Tofidence, Tyenne)

IVX HEALTH

Provider Order Form *rev. 2/6/26*

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Date: Patient Name: DOB:

ICD-10 code (required): ICD-10 description:

☐ NKDA Allergies: Weight (lbs/kg): Height:

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: Next Due Date:

PROVIDER INFORMATION

Referral Coordinator Name: Referral Coordinator Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

NURSING

☑ TB status & date (list results here & attach clinicals)

_____

☑ Provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation
NOTE: IVX Adverse Reaction Management Protocol available for review at www.ivxhealth.com/forms (version 05.01.2023)

LABORATORY ORDERS

☐ CBC ☐ at each dose ☐ every _____
☐ CMP ☐ at each dose ☐ every _____
☐ CRP ☐ at each dose ☐ every _____
☐ Other: _____

PRE-MEDICATION ORDERS

☐ acetaminophen (Tylenol) ☐ 500mg / ☐ 650mg / ☐ 1000mg PO
☐ cetirizine (Zyrtec) 10mg PO
☐ loratadine (Claritin) 10mg PO
☐ diphenhydramine (Benadryl) ☐ 25mg / ☐ 50mg ☐ PO / ☐ IV
☐ methylprednisolone (Solu-Medrol) ☐ 40mg / ☐ 125mg IV
☐ hydrocortisone (Solu-Cortef) ☐ 100mg IV
☐ Other: _____
Dose: _____ Route: _____
Frequency: _____

THERAPY ADMINISTRATION

Tocilizumab (Actemra) or other tocilizumab product (as required by patient's health plan)

NOTE: Tocilizumab products include Actemra, Tofidence, and Tyenne

- Dose: ☐ 4mg/kg / ☐6mg/kg ☐ 8mg/kg / ☐ 10mg/kg / ☐ 12mg/kg
- Frequency: ☐ every 2 weeks / ☐ every 4 weeks / ☐ other: _____
- Route: intravenous
- Infuse over 1 hour
- ☑ Flush with 0.9% sodium chloride at infusion completion
- Doses exceeding 800mg per infusion are not recommended in RA patients
- Doses exceeding 600mg per infusion are not recommended in GCA patients

☐ Refills: ☐ Zero / ☐ for 12 months / ☐ _____ (if not indicated order will expire one year from date signed)

APPEALS PROCESS

Upon denial, IVX will appeal with a Letter of Medical Necessity unless you opt out: ☐ Opt out (I will manage any denial)

SPECIAL INSTRUCTIONS

Perform test for latent TB; if positive, start treatment for TB prior to starting tocilizumab. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

It is recommended that tocilizumab not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN).

Laboratory monitoring—recommended due to potential consequences of treatment-related changes in neutrophils, platelets, lipids, and liver function tests.

Provider Name (Print) **Provider Signature** **Date**

IVX HEALTH FAX NUMBERS

☐ ARKANSAS: 501-451-5644
☐ AUSTIN: 512-772-2824
☐ BAY AREA: 844-889-0275
☐ CHARLOTTE: 336-663-0143
☐ CHICAGO: 312-253-7244
☐ CINCINNATI: 844-946-0868
☐ COLLEGE STN: 979-205-4686
☐ COLUMBUS: 844-627-2675
☐ CONNECTICUT: 860-955-1532
☐ DALLAS: 469-947-6114
☐ DAYTONA: 386-259-6096
☐ DELAWARE: 302-596-8553
☐ EAST TN/TRI-CITIES: 615-425-7427
☐ FT. LAUDERDALE: 754-946-2052
☐ HARRISBURG: 844-859-4235
☐ HOUSTON: 832-631-9595
☐ INDIANAPOLIS: 844-983-2028
☐ JACKSONVILLE: 904-212-2338
☐ KANSAS CITY: 844-900-1292
☐ LAKELAND: 863-316-3910
☐ MELBOURNE: 321-800-9515
☐ MIAMI: 786-744-5687
☐ MIDDLE/WEST TN: 888-615-1445
☐ NORTH CENTRAL FL: 352-756-4191
☐ NORTH JERSEY: 551-227-2823
☐ NYC: 332-334-0809
☐ ORLANDO: 844-946-0867
☐ PALM BEACH: 561-768-9044
☐ PHILADELPHIA: 844-820-9641
☐ PIEDMONT TRIAD: 336-790-2200
☐ RALEIGH: 919-287-2551
☐ SAN ANTONIO: 726-238-9950
☐ SARASOTA: 941-870-6550
☐ SOUTH JERSEY: 856-519-5309
☐ SOUTHWEST FL: 813-283-9144
☐ TAMPA: 844-946-0849
☐ WACO: 254-343-7650